
0:00
33:15
Welcome to Part 1 of our Peptide Series, where we break down the science behind today’s most talked-about compounds–starting with retatrutide.
In this episode, we dive into the mechanism of action of retatrutide, the first GLP-1, GIP, and glucagon triple agonist, and why it represents a major shift in obesity pharmacology.
We cover:
- What GLP-1, GIP, and glucagon receptors actually do
- How retatrutide drives satiety, insulin signaling, and energy expenditure simultaneously
- Why adding glucagon changed the game
- A clear breakdown of the clinical trial data so far
- How retatrutide compares to current drugs like semaglutide and tirzepatide
This episode is your mechanism-first foundation for understanding where peptide-based fat loss is headed.
1:1 COACHING:
- email: [email protected]
SHOP MY NEW 'NUTRITION NAVIGATED' E-BOOK!
STRENGTH & HYPERTROPHY TRAINING PROGRAM:
MY SOCIALS:
- IG:@Vallfitt_ifbbpro
- Tiktok: @Vallfitt
- YouTube: VallFitt
CONTACT ME:
- [email protected]
- IG: @TheValidityPodcast
STUDIES/CLINICAL TRIALS:
- PMID: 37366315
- PMID: 37385280
- PMID: 41090431
- PMID: 38367045
Altri episodi di "The VALidity Podcast"



Non perdere nemmeno un episodio di “The VALidity Podcast”. Iscriviti all'app gratuita GetPodcast.








